How to treat insomnia: what a genetic health test can offer in your case

Insomnia has a clear biological basis as well as lifestyle influences: twin studies and large genome-wide association studies (GWAS) show that there is a genetic predisposition to insomnia, but not everyone with that predisposition develops it. This is why, when considering how to treat insomnia, it starts to make sense to ask what information a genetic health test can provide to prevent it or manage it in a more personalised way.

“A genetic test does not tell you whether you will develop insomnia; it shows you how much underlying vulnerability you have, so that you can prevent and treat it as intelligently as possible”.

Insomnia and genetics: why people do not all respond in the same way

Large-scale genetic studies have identified hundreds of variants associated with the risk of insomnia, many of them related to brain pathways involved in the regulation of sleep, mood and metabolism.

These data have been used to develop polygenic risk scores for insomnia, which make it possible to estimate who has a greater predisposition to developing chronic sleep problems during their lifetime.

This does not mean that the test “diagnoses” insomnia; rather, it helps us understand:

• Who may be more vulnerable to stress, changes in schedules or certain habits eventually triggering insomnia.
• Why some people seem to “cope better” with the same circumstances without developing sleep problems.

How a genetic test may help prevent insomnia

When it comes to prevention, a genetic health test focused on sleep and insomnia can provide several layers of useful information when interpreted alongside the medical history:

• Identifying greater susceptibility to insomnia: a high risk score may justify being more proactive about sleep hygiene, stress management and adjusting schedules, especially during life changes (shift work, parenthood, menopause, etc.).
• Connecting insomnia with other associated risks: genetic studies show a correlation between insomnia and the risk of depression, anxiety disorders and some cardiovascular diseases, reinforcing the importance of prevention in people with greater susceptibility.
• Prioritising lifestyle interventions: in people with a high predisposition, strengthening the pillars of lifestyle (sleep, physical activity, diet, light and stress) earlier and more intensively may reduce the likelihood of insomnia becoming chronic.

In this context, the test does not replace general advice on healthy sleep, but helps determine where to focus and how intensively.

How to treat insomnia once it has developed: the role of genetics

When insomnia is already present, the evidence continues to indicate that the first-line treatment is cognitive behavioural therapy for insomnia (CBT‑I). However, genetics may inform some decisions:

• Susceptibility profile: in people with a strong genetic predisposition, it makes even more sense to favour structured interventions such as CBT‑I rather than relying solely on general measures or occasional medication.
• Comorbidities: the genetic correlation between insomnia and other traits (such as frailty or certain mood disorders) suggests that, in some profiles, it may be useful to assess factors such as mood, chronic pain or cardiovascular disease risk from the outset.

In other words, a genetic test does not replace therapy or good sleep practices, but helps build a more complete picture of the patient with insomnia, especially when there is uncertainty about the relative influence of biological and environmental factors.

Genetics, medication and insomnia: why responses differ

Another area in which genetics may influence how insomnia is treated is the response to certain medications. Research in pharmacogenetics shows that variants in genes involved in drug metabolism or transport may alter the response to, and tolerance of, medications used for sleep disorders or associated comorbidities (such as anxiolytics and antidepressants).

Although the evidence specific to hypnotics is still limited and developing, these data support the idea that, in some patients, a pharmacogenetic analysis could help to:

• Avoid medications with a higher risk of adverse effects for their profile.
• Optimise doses or choose alternatives when tolerance is poor.

In any case, guidelines continue to recommend limiting prolonged use of hypnotics and focusing the treatment of chronic insomnia on non-pharmacological interventions such as CBT‑I.

What a genetic test can and cannot promise for insomnia

To use this tool well, it is essential to be clear about its limitations:

• A genetic test does not “cure” insomnia, nor does it replace therapy or lifestyle changes.
• Risk scores for insomnia explain part of the variability; the rest depends on environmental and psychological factors and other aspects of health.
• Its value lies in personalising prevention and management, identifying who should be monitored more closely, who would benefit from earlier and more intensive structured interventions, or when it may also be worth exploring pharmacogenetics.

How to integrate a genetic test into the approach to insomnia

In practice, appropriate use of genetics in insomnia can follow this approach:

1. Comprehensive clinical assessment: sleep history, triggers, medical and psychiatric comorbidities, medications and lifestyle habits.
2. Genetic health test: a panel that includes insomnia risk and, where appropriate, pharmacogenetics relevant to associated treatments, only if necessary.
3. Integrated interpretation: combine genetic results with the clinical picture to estimate susceptibility, potential comorbidities and associated risks.
4. Personalised plan:
   • CBT‑I as the foundation for treating chronic insomnia.
   • Specific lifestyle adjustments (schedules, light, exercise, caffeine and alcohol), particularly for people with greater genetic vulnerability.
   • Cautious and personalised use of medication when necessary, considering any available pharmacogenetic information.

Genetics adds context and priorities; the pillars remain the same, but are better targeted to each person.